Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
Hamza Mohamed, Medical Director and Medical Resident St. Paulos MMH at Ethiopian Health professionals’ Associations, shared a post on LinkedIn:
“Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute Pulmonary Embolism (PE)
The 2026 AHA/ACC guideline represents the first comprehensive U.S. clinical practice guideline dedicated entirely to the evaluation and management of acute pulmonary embolism. It introduces several important practice-changing recommendations.
1. A new PE classification replaces ‘massive’ and ‘submassive’
The guideline introduces AHA/ACC Acute PE Clinical Categories (A–E), providing a more precise framework based on clinical severity, RV dysfunction, biomarkers, and hemodynamic status to guide management.
2. More patients can be treated as outpatients
- Category A: Asymptomatic PE – safe ED discharge.
- Category B: Symptomatic but low-risk PE – early discharge is generally recommended.
This highlights a shift toward individualized, resource-conscious care.
3. PE Response Teams (PERTs) receive a Class I recommendation
Multidisciplinary PE teams are now strongly recommended to facilitate rapid risk stratification and timely treatment decisions.
4. Anticoagulation updates
- LMWH is preferred over UFH when initial parenteral anticoagulation is needed (unless specific indications for UFH exist).
- DOACs are preferred over warfarin in eligible patients because they reduce recurrent VTE and major bleeding.
5. Advanced reperfusion therapies
Systemic thrombolysis, catheter-directed therapies, mechanical thrombectomy, and surgical embolectomy should be selected according to the new A–E risk categories, with the strongest role in patients with hemodynamic compromise.
6. Extended anticoagulation
Patients with a first unprovoked PE or persistent risk factors should generally continue anticoagulation beyond the initial 3–6 months, after balancing bleeding risk.
7. Long-term follow-up is now emphasized
Patients should be assessed for persistent dyspnea and functional limitation for at least 12 months to detect chronic thromboembolic pulmonary disease (CTEPD) or other post-PE complications.
Take-home message:
The 2026 guideline moves PE management toward precision medicine—replacing outdated terminology, expanding outpatient management for low-risk patients, prioritizing multidisciplinary care, and strengthening long-term follow-up.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support